Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-Label,Randomised, Comparator Study of Substitution w/Tenofovir or Abacavir in HIV-1 Infected Individuals, w/Viral Load Less 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of HAART.

NCT00270556 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00270556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00270556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-Label,Randomised, Comparator Study of Substitution w/Tenofovir or Abacavir in HIV-1 Infected Individuals, w/Viral Load Less 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of HAART.
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2003
Completion date
October 31, 2004
Enrollment
100
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv